09:44 AM EST - Valeant Pharmaceuticals International, Inc. : Announced second-quarter financial results. Total revenue was $2.7 billion; an increase of 34% over the prior year. Operating income was $341.5 million, down from $355.1 million in the prior-year quarter. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading unchanged at $312.25.
